The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Ceftotan     (7R)-7-[[4-(aminocarbonyl- carboxy...

Synonyms: NSC-760045, NSC760045, LS-149944, ICI 156834, DB01330, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of cefotetan


Psychiatry related information on cefotetan

  • Cefotetan inhibited beta-lactamases of the type Ia and Id, but it also induced these beta-lactamases in P. aeruginosa, E. cloacae and C. freundii [6].

High impact information on cefotetan


Chemical compound and disease context of cefotetan


Biological context of cefotetan


Anatomical context of cefotetan


Associations of cefotetan with other chemical compounds


Gene context of cefotetan

  • Cefotetan MICs of >/= 8 microg/ml were obtained for seven of eight producers of AmpC beta-lactamase and no ESBL producers [26].
  • In the presence of temperature-sensitive ampD, induction by cefotetan was similar to that by cefoxitin at 30 degrees C but greater than that by cefoxitin at 42 degrees C. These results suggest that ampD encodes a protein involved in induction of AmpC beta-lactamase in E. cloacae [27].
  • Upon closure of the abdomen (216 +/- 76 min), cefotetan concentrations were 6.3 +/- 3 micrograms/g in abdominal-wall fat, 6.1 +/- 4 micrograms/g in epiploic fat, and 64 +/- 38 mg/liter in serum [8].
  • Meropenem and imipenem were highly resistant to the hydrolytic activity of all the TEM and SHV related beta-lactamases, and to the OXA enzymes, as were the cephamycins: cefoxitin and cefotetan [28].
  • Drug-independent antibodies (i.e., those reacting without any drug being present) were detected in 33 to 44 percent of patients' sera containing cefotetan antibodies, depending on the sensitivity of the method used [29].

Analytical, diagnostic and therapeutic context of cefotetan


  1. Cefotetan and hypoprothrombinemia. Conjura, A., Bell, W., Lipsky, J.J. Ann. Intern. Med. (1988) [Pubmed]
  2. In vitro activity of cefbuperazone compared with that of other new beta-lactam agents against anaerobic gram-negative bacilli and contribution of beta-lactamase to resistance. Del Bene, V.E., Carek, P.J., Twitty, J.A., Burkey, L.J. Antimicrob. Agents Chemother. (1985) [Pubmed]
  3. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein. Bradford, P.A., Urban, C., Mariano, N., Projan, S.J., Rahal, J.J., Bush, K. Antimicrob. Agents Chemother. (1997) [Pubmed]
  4. In vitro activity of cefotetan compared with that of other antimicrobial agents against anaerobic bacteria. Wexler, H.M., Finegold, S.M. Antimicrob. Agents Chemother. (1988) [Pubmed]
  5. Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Ward, A., Richards, D.M. Drugs (1985) [Pubmed]
  6. The activity and beta-lactamase stability of cefotetan compared to other beta-lactam antibiotics. Neu, H.C., Chin, N.X. Chemioterapia : international journal of the Mediterranean Society of Chemotherapy. (1985) [Pubmed]
  7. Clinical pharmacokinetics of cefotetan. Martin, C., Thomachot, L., Albanese, J. Clinical pharmacokinetics. (1994) [Pubmed]
  8. Pharmacokinetics and tissue penetration of single-dose cefotetan used for antimicrobial prophylaxis in patients undergoing colorectal surgery. Martin, C., Portet, C., Lambert, D., Bruguerolle, B., Sastre, B., De Micco, P., Gouin, F. Antimicrob. Agents Chemother. (1992) [Pubmed]
  9. Serum and blister fluid pharmacokinetics and bactericidal activities of ampicillin-sulbactam, cefotetan, cefoxitin, ceftizoxime, and ticarcillin-clavulanate. Jaresko, G.S., Barriere, S.L., Johnson, B.L. Antimicrob. Agents Chemother. (1992) [Pubmed]
  10. Activities of cefoxitin and cefotetan against Mycobacterium fortuitum infections in mice. Saito, H., Sato, K., Jin, B.W. Antimicrob. Agents Chemother. (1984) [Pubmed]
  11. In vitro activity of cefmetazole, cefotetan, amoxicillin-clavulanic acid, and other antimicrobial agents against anaerobic bacteria from endometrial cultures of women with pelvic infections. Ohm-Smith, M.J., Sweet, R.L. Antimicrob. Agents Chemother. (1987) [Pubmed]
  12. Beta-lactamase stability of temocillin. Edmondson, R.A., Reading, C. Drugs (1985) [Pubmed]
  13. Emerging resistance of anaerobic bacteria to antimicrobial agents in South Korea. Lee, K., Chong, Y., Jeong, S.H., Xu, X.S., Kwon, O.H. Clin. Infect. Dis. (1996) [Pubmed]
  14. Cefotetan: antimicrobial activity in-vitro compared with that of cefotaxime. Dette, G.A., Knothe, H., Henckel, S. J. Antimicrob. Chemother. (1983) [Pubmed]
  15. Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia. Kline, S.S., Mauro, V.F., Forney, R.B., Freimer, E.H., Somani, P. Antimicrob. Agents Chemother. (1987) [Pubmed]
  16. Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing. Ayers, L.W., Jones, R.N., Barry, A.L., Thornsberry, C., Fuchs, P.C., Gavan, T.L., Gerlach, E.H., Sommers, H.M. Antimicrob. Agents Chemother. (1982) [Pubmed]
  17. Results of a multicenter comparative study of single-dose cefotetan and multiple-dose cefoxitin as prophylaxis in patients undergoing cesarean section. Galask, R.P., Benigno, B.B., Cunningham, F.G., Elliott, J.P., Makowski, E., McGregor, J.A., Poindexter, A. Am. J. Surg. (1988) [Pubmed]
  18. Pharmacokinetics and tissue kinetics of 1 gm cefotetan prophylaxis in abdominal or vaginal hysterectomy. Orr, J.W., Sisson, P.F., Barrett, J.M., Ellington, J.R., Jennings, R.H., Taylor, D.L. Am. J. Obstet. Gynecol. (1988) [Pubmed]
  19. The pharmacokinetics of cefotetan excretion in the unobstructed biliary tree. Owen, A.W., Manson, J.M., Yates, R.A., Adshead, V.M., Houghton, H.L., Tweedle, D.E. J. Antimicrob. Chemother. (1983) [Pubmed]
  20. Persistence of cefotetan on red blood cells. Davenport, R.D., Judd, W.J., Dake, L.R. Transfusion (2004) [Pubmed]
  21. Comparative effects of cefoxitin and cefotetan on vitamin K metabolism. Sieradzan, R.R., Bottner, W.A., Fasco, M.J., Bertino, J.S. Antimicrob. Agents Chemother. (1988) [Pubmed]
  22. Pharmacokinetics of cefotetan (YM09330) in humans. Nakagawa, K., Koyama, M., Tachibana, A., Komiya, M., Kikuchi, Y., Yano, K. Antimicrob. Agents Chemother. (1982) [Pubmed]
  23. Comparative antibacterial activities of 7 alpha-methoxy cephalosporins and 7 beta-methoxyiminoacetamido cephalosporins against Bacteroides fragilis. Kesado, T., Watanabe, K., Asahi, Y., Isono, M., Ueno, K. Antimicrob. Agents Chemother. (1984) [Pubmed]
  24. In vitro activity of cefotetan, a new cephamycin derivative, compared with that of other beta-lactam compounds. Wise, R., Andrews, J.M., Hancox, J. Antimicrob. Agents Chemother. (1982) [Pubmed]
  25. Comparative evaluation of the pharmacokinetics of N-methylthiotetrazole following administration of cefoperazone, cefotetan, and cefmetazole. Welage, L.S., Borin, M.T., Wilton, J.H., Hejmanowski, L.G., Wels, P.B., Schentag, J.J. Antimicrob. Agents Chemother. (1990) [Pubmed]
  26. Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam? Moland, E.S., Sanders, C.C., Thomson, K.S. J. Clin. Microbiol. (1998) [Pubmed]
  27. Altered phenotypes associated with ampD mutations in Enterobacter cloacae. Korfmann, G., Sanders, C.C., Moland, E.S. Antimicrob. Agents Chemother. (1991) [Pubmed]
  28. Interactions of meropenem, with beta-lactamases, including enzymes with extended-spectrum activity against third-generation cephalosporins. Labia, R., Morand, A., Tiwari, K., Sirot, D., Chanal, C. J. Antimicrob. Chemother. (1989) [Pubmed]
  29. Serology of antibodies to second- and third-generation cephalosporins associated with immune hemolytic anemia and/or positive direct antiglobulin tests. Arndt, P.A., Leger, R.M., Garratty, G. Transfusion (1999) [Pubmed]
  30. Cefotetan pharmacokinetics in volunteers with various degrees of renal function. Smith, B.R., LeFrock, J.L., Thyrum, P.T., Doret, B.A., Yeh, C., Onesti, G., Schwartz, A., Zimmerman, J.J. Antimicrob. Agents Chemother. (1986) [Pubmed]
  31. Intraperitoneal penetration of cefotetan. Wise, R., Donovan, I.A., Drumm, J., Dent, J., Bennett, S.A. Antimicrob. Agents Chemother. (1983) [Pubmed]
  32. Cefazolin is inferior to cefotetan as single-dose prophylaxis for women undergoing elective total abdominal hysterectomy. Hemsell, D.L., Johnson, E.R., Hemsell, P.G., Nobles, B.J., Little, B.B., Heard, M.C. Clin. Infect. Dis. (1995) [Pubmed]
WikiGenes - Universities